Valuation : Black Diamond Therapeutics, Inc.

Market Cap 121M 104M 97.68M 89.23M 167M 11.39B 167M 1.15B 448M 5.84B 453M 443M 18.83B P/E 2026 *
-3.41x
P/E 2027 * -2.2x
Enterprise Value 121M 104M 97.68M 89.23M 167M 11.39B 167M 1.15B 448M 5.84B 453M 443M 18.83B EV / Sales 2026 *
19.3x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+1.67%
1 week-4.26%
Current month+1.67%
1 month+19.94%
3 months+2.15%
6 months-13.21%
Current year-12.14%
1 week 2.02
Extreme 2.02
2.22
1 month 1.76
Extreme 1.76
2.32
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/3/26
NEA Management Co. LLC
OtherCompany 0 0% -
20/3/26 Free

Director

6,105 0.0107%
20/3/26 Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%-4.26%-25.61%-39.35% 121M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.44%+6.12%-11.74%+377.06% 27.66B
+1.61%+2.31%+0.90%-14.40% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.11%+8.42%+57.93%+165.09% 14.65B
Average -1.01%-1.34%+36.87%+157.59% 28.33B
Weighted average by Cap. -1.48%-0.46%+39.05%+138.96%

Financials

2026 *2027 *
Net sales 6.25M 5.38M 5.06M 4.62M 8.65M 590M 8.67M 59.79M 23.2M 303M 23.47M 22.96M 975M -
Net income -36.96M -31.81M -29.93M -27.34M -51.14M -3.49B -51.28M -354M -137M -1.79B -139M -136M -5.77B -64.65M -55.63M -52.34M -47.81M -89.44M -6.1B -89.69M -618M -240M -3.13B -243M -237M -10.09B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
05/09/26 US$2.145 +2.14% 133,832
03/09/26 US$2.100 -1.87% 609,843
02/09/26 US$2.140 +4.90% 561,275
01/09/26 US$2.040 -2.86% 759,127
31/08/26 US$2.100 -5.83% 509,283
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.100USD
Average target price
10.00USD
Spread / Average Target
+376.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock